Zhang Z.-Q.,The 305 Hospital of Chinese PLA |
Zhang B.,The Affiliated Hospital of Academy of Military Medical science |
Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental hematology / Chinese Association of Pathophysiology | Year: 2014
Dendritic cells can be derived from leukemia cells and normal precursor cells in the patients with acute myeloid leukemia (AML). Dendritic cells may capture leukemia antigen in bone marrow or lymph nodes, and present leukemia common antigen to stimulate proliferation of specific CD8(+) T cells, playing anti-leukemia effect. Dendritic cells for clinical and experimental use are transformed from leukemia cells and peripheral blood mononuclear cells and loaded in vitro with leukemia -specific or tumor common antigen, play a therapeutic role after reinfusion. This article reviews dendritic cells in the immunotherapy of AML.
He W.,The 305 Hospital of Chinese PLA |
Wang M.,Chinese Peoples Armed Police forces Academy |
Wang Y.,Shanghai University |
wang Q.,Chinese Peoples Armed Police forces Academy |
Luo B.,Peoples Hospital of Poyang Country
Journal of Arthroplasty | Year: 2016
Background: The aim is to determine whether CXC chemokine ligand-12 (CXCL12) levels in plasma and synovial fluid (SF) of patients with knee osteoarthritis (OA) are correlated with the disease severity. In addition, we set out to investigate whether a peripheral blood test can avoid aspirating patients to determine CXCL12 levels. Methods: This study consisted of 244 patients with knee OA and 244 age- and gender-matched healthy controls. Osteoarthritis progression was classified based on Kellgren-Lawrence (KL) by evaluating radiographic changes observed in anteroposterior knee radiography. The CXCL12 levels in the plasma and SF were measured by a quantitative sandwich enzyme-linked immunosorbent assay. Results: Plasma CXCL12 levels were higher in OA patients as compared with controls (< .0001). There was a positive correlation between levels of CXCL12 and grade (< .0001). Base on the receiver operating characteristic curve, the optimal cutoff value of plasma CXCL12 levels as an indicator for screening of OA was estimated to be 5.5 ng/mL, which yielded a sensitivity of 78.4% and a specificity of 80.2%, with the area under the curve at 0.850 (95% confidence interval [CI], 0.816-0.889; P < .0001). In multivariate analysis, there was an increased risk of active OA associated with plasma CXCL12 levels ≥. 10.5 ng/mL (odds ratio, 6.76; 95% CI, 3.88-12.53; P < .0001) after adjusting for possible confounders. Similarly, there was an increased risk of active OA associated with SF CXCL12 levels ≥. 15.0 ng/mL (odds ratio, 8.45; 95% CI, 3.23-18.22; P < .0001) after adjusting for possible confounders. Conclusion: The CXCL12 levels in the plasma and SF may serve as effective biomarkers for the severity of OA. © 2016 Elsevier Inc.
He W.,The 305 Hospital of Chinese PLA |
Liu M.,The 305 Hospital of Chinese PLA
Chinese Journal of Tissue Engineering Research | Year: 2013
Background: Modified medical adhesives with α-cyanoacrylate as the main component can produce a large adhesive strength in a moist environment, such as carrying different types of drugs, achieving a sustained release of drug and inducing the creeping substitution of new bone tissue. Objective: To analyze the physical and chemical characteristics of cyanoacrylate-nano drug delivery system so as to clarify its clinical prospect in the future and problems to be solved. Methods: A computer-based online search of PubMed, CNKI databases was performed for articles published from January 2004 to October 2012 using the key words of "cyanoacrylate; nanoparticle drug delivery system; targeted therapy" in English and Chinese, respectively. Articles related to cyanoacrylate and nano-drugs bone targeted therapy were included. Results and Conclusion: In view of cyanoacrylate and its derivatives can be bonded quickly in the bone marrow cavity under moist conditions, have larger strength and can be degraded, cyanoacrylate-nano drug is used for bone targeted therapy. The FDA has upgraded cyanoacrylate applicable level from Class III to Class II. Future issues could make full use of the advantages of nano-drug targeted therapy, to achieve high drug load and controlled drug release; carry out interdisciplinary research to improve bonding strength, biomechanical strength and elastic modulus of bone-prosthesis interface; develop composite biomaterials thereby to improve the deficiency of single materials in performance. Compound nano-drug targeted therapy will be a great potential way to the treatment of bone tumors, bone tuberculosis and osteomyelitis.
Sun Z.-y.,The 305 Hospital of Chinese PLA |
Zhang M.-r.,The 305 Hospital of Chinese PLA |
Chen G.,The 305 Hospital of Chinese PLA |
Wang D.-f.,The 305 Hospital of Chinese PLA |
And 2 more authors.
Journal of Clinical Rehabilitative Tissue Engineering Research | Year: 2011
BACKGROUND: CAD-CAM template-guided flapless implantation can ensure reliable transfer of preoperative computer-assisted planning into surgical practice. A new type of template-guided flapless implant placement using a CAM model-based planning procedure can also be used in sites with insufficient bone volume. OBJECTIVE: By observing the clinical results of flapless implant operation with implant navigation in the areas of maxillary premolar, which have relatively insufficient bone width, to evaluate the clinical feasibility of this method. METHODS: A total of eight patients who had lost 10 maxillary premolars were treated with the operations. The average height of premolar alveolar bone was (13.45±1.67) mm. By using craniofacial CT scan, three-dimensional reconstruction analysis and sham-operated analysis of rapid prototyping models, we obtained the accurate datum of the length, width, height and angle of the alveolar bone. RESULTS AND CONCLUSION: The surgical guides had sufficient retention which was easy to place and remove on the teeth. Compared with the sham-operated analysis of models, all the implants of the 10 teeth had been implanted accurately. The average operation time was (17.0 ± 5.8) minutes. Except for one patient who had a residual root under the mucosa of maxillary sinus, the length of the implants in the alveolar bone was all more than 13 mm, without the occurrence of penetration of mucosa of maxillary sinus, perforation of bone lamella and other complications. And all the patients only had mild swelling and pain. Ten porcelain crowns were placed 3 to 6 months later. With the guidance of guide plates, the implants can be accurately implanted into the insufficient bone by application of flapless implant operation. This method may have great technical advantages and broad prospects in curing the patients with alveolar bone atrophy and insufficient available bone.